Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostate brachytherapy. An overview

A T Porter1, J D Forman

  • 1Department of Radiation Oncology, Wayne State University, Detroit, MI 48201.

Cancer
|February 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An unusual cause of increased abdominal girth.

QJM : monthly journal of the Association of Physicians·2008
Same author

Radiologic validation of a fast neutron multileaf collimator.

Medical physics·2007
Same author

The proposed tobacco settlement.

The Journal of oncology management : the official journal of the American College of Oncology Administrators·2006
Same author

Compact multileaf collimator for conformal and intensity modulated fast neutron therapy: electromechanical design and validation.

Medical physics·2006
Same author

Therapeutic Strategies for Localized Prostate Cancer II: Perineal Prostatectomy, X-Rays, Protons, Neutrons, and Combination Brachytherapy.

Reviews in urology·2006
Same author

Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: an analysis of RTOG 8610.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2003
Same journal

Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

Cancer·2026
Same journal

Large-scale osteosarcoma sequencing reveals age-associated genomic architectures.

Cancer·2026
Same journal

EZH2 inhibitor tazemetostat voluntarily withdrawn from market.

Cancer·2026
Same journal

Nivolumab and chemotherapy combination approved for previously untreated Hodgkin lymphoma.

Cancer·2026
Same journal

Most older patients with advanced cancer prioritize QOL over extending survival: A secondary analysis of the GAP70+ trial found that among adults aged 70 and older with advanced, noncurable cancer, nearly three-quarters prioritized maintaining QOL.

Cancer·2026
Same journal

Real-world safety, prognostic, and design considerations in ketogenic diet trials for pancreatic cancer.

Cancer·2026
See all related articles

Prostate brachytherapy, a radiation treatment for prostate cancer, has evolved with new isotopes and techniques. Higher dose rate sources may improve cancer control, but iodine-125 has shown limited success in aggressive cases.

Area of Science:

  • Oncology
  • Radiation Oncology
  • Medical Physics

Background:

  • Prostate brachytherapy is a long-standing radiation therapy for prostate cancer.
  • Recent advancements include new radioactive isotopes, afterloading techniques, and radiobiology insights.
  • Understanding dose rates is crucial for effective treatment.

Purpose of the Study:

  • To review the evolution and current applications of prostate brachytherapy.
  • To discuss the impact of new technologies and isotopes on treatment outcomes.
  • To define the role of brachytherapy in managing prostate cancer, particularly bulky neoplasms.

Main Methods:

  • Prostate brachytherapy involves temporary (e.g., iridium-192) or permanent (e.g., iodine-125, palladium-103) implantation.
  • Insertion techniques include open/closed procedures via suprapubic or perineal/retropubic approaches.

Related Experiment Videos

  • Remote afterloading minimizes radiation protection concerns.

    • Main Results:

    • Treatment outcomes with brachytherapy isotopes are variable.
    • Higher dose rate sources and high integral doses may enhance histologic control.
    • Permanent iodine-125 implantation has not been successful for aggressive prostate cancer.

    Conclusions:

    • Brachytherapy remains a valuable treatment option for prostate cancer.
    • Its role is increasingly defined for large, bulky tumors.
    • Improved dose distribution between normal and tumor tissues is a key benefit.